Source link : https://www.newshealth.biz/health-news/delgocitinib-effective-for-hand-eczema-in-phase-3-studies/
TOPLINE: Topical delgocitinib, a pan-Janus kinase inhibitor, was well tolerated and reduced the severity and symptoms of disease in patients with moderate to severe chronic hand eczema, in two phase 3 trials. METHODOLOGY: Two randomized, multinational, double-blinded, vehicle-controlled, phase 3 trials, DELTA 1 (n = 487) and DELTA 2 (n = 473) enrolled adults (mean […]
Author : News Health
Publish date : 2024-07-24 03:00:43
Copyright for syndicated content belongs to the linked Source.
inHealth